We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mayne Pharma Group Ltd | ASX:MYX | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 3.35% | 4.63 | 4.63 | 4.67 | 4.68 | 4.47 | 4.50 | 331,365 | 09:50:00 |
From Jun 2019 to Jun 2024
By Rebecca Thurlow
SYDNEY--Mayne Pharma Group Ltd. (MYX.AU) said Wednesday it has launched its foam dermatology products Fabior and Sorilux in the U.S., after acquiring the marketing rights from GlaxoSmithKline (GSK) in August.
Fabior is a topical treatment for acne, the most prevalent skin disease in the U.S., affecting as many as 50 million people.
The market for topical acne treatments is significantly larger than the oral antibiotic acne market Mayne already participates in via the sale of its Doryx branded products. Topical products are used more frequently by acne patients across the disease spectrum ranging from mild to severe cases, Mayne said.
Sorilux is a foam that treats plaque psoriasis of the scalp and body, which affects up to six million Americans each year.
- Write to Rebecca Thurlow at rebecca.thurlow@wsj.com
(END) Dow Jones Newswires
January 10, 2017 17:13 ET (22:13 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Mayne Pharma Chart |
1 Month Mayne Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
